ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has reported promising results from its Phase Ib/IIa clinical trial of IMM0306, a bispecific molecule for treating indolent lymphoma. The trial demonstrated an 84% overall response rate in follicular lymphoma patients, with a 100% rate in marginal zone lymphoma cases, showcasing significant efficacy. The company continues active enrollment and observation in this study.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.